Compare Ross Stores, Inc. (ROST) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ross Stores, Inc. vs Smith & Nephew plc — how do they compare? Ross Stores, Inc. trades at $226 (market cap $71.94B), while Smith & Nephew plc trades at $27.17 (market cap $11.10B). The key difference: Ross Stores, Inc. is far larger — about 6.5× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold Ross Stores, Inc. for 48 Days and Smith & Nephew plc for 120 Days on average.
| ROST | SNN | |
|---|---|---|
Market Cap | $71.94B | $11.10B |
Volume | 2,002,519 | 1,051,703 |
Sector | Consumer Cyclical | Health |
52-Week High | $255.23 | $37.17 |
52-Week Low | $147.71 | $26.42 |
Typical Hold Time | 48 Days | 120 Days |
Enterprise Value | $72.39B | $14.13B |
Dividend Yield | 0.79% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ross Stores (ROST) trades at $225.53, up 0.59% today, with a bearish technical signal but strong fundamental performance. The stock shows robust profitability with a net income margin of 10.85% and ROE of 42.63%, supported by consistent earnings beats in recent quarters. Revenue growth trends upward, reaching $21.13B in 2025, while analyst consensus remains bullish with a $274.14 price target. Recent news highlights store expansion and value-focused strategies attracting shoppers amid competitive retail pressures.
The outlook for ROST is positive based on earnings momentum and strategic initiatives, though technical indicators suggest near-term caution. Risks include rising costs and market volatility, but institutional buying and high ROE provide support. The stock offers growth potential if execution on expansion continues, with downside cushioned by strong cash flow and analyst optimism.
Smith & Nephew (SNN) trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio, though the stock faces headwinds from analyst downgrades and CFO departure news.
The outlook is cautious; while fundamentals show profitability growth, the stock's proximity to lows and mixed analyst sentiment (26% buy, 65% hold) suggest limited near-term upside. Key risks include competitive pressures and execution challenges, but the stable dividend and institutional interest offer some support for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Ross Stores, Inc.
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
